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BACKGROUND: The sodium/glucose cotransporter 2 inhibitor empagliflozin has cardiorenal protective properties through mecha-
nisms beyond glucose control. In this study we assessed whether empagliflozin modifies renal oxygenation as a possible mecha-
nism of renal protection, and determined the metabolic, renal, and hemodynamic effects of empagliflozin in nondiabetic subjects.
METHODS AND RESULTS: In this double- blind, randomized, placebo- controlled study, 45 healthy volunteers underwent blood 
and urine sampling, renal ultrasound, and blood- oxygenation- level–dependent magnetic resonance imaging before and 
180 minutes after administration of 10 mg empagliflozin (n=30) or placebo (n=15). These examinations were repeated after 
1 month of daily intake. Cortical and medullary renal oxygenation were not affected by the acute or chronic administration of 
empagliflozin, as determined by 148 renal blood- oxygenation- level–dependent magnetic resonance imaging examinations. 
Empagliflozin increased glucosuria (24- hour glucosuria at 1 month: +50.1±16.3 g). The acute decrease in proximal sodium 
reabsorption, as determined by endogenous fractional excretion of lithium (−34.6% versus placebo), was compensated at 1 
month by a rise in plasma renin activity (+28.6%) and aldosterone (+55.7%). The 24- hour systolic and diastolic ambulatory 
blood pressures decreased significantly after 1 month of empagliflozin administration (−5.1 and −2.0 mm Hg, respectively). 
Serum uric acid levels decreased (−28.4%), hemoglobin increased (+1.7%), and erythropoietin remained the same.
CONCLUSIONS: Empagliflozin has a rapid and significant effect on tubular function, with sustained glucosuria and transient 
natriuresis in nondiabetic normotensive subjects. These effects favor blood pressure reduction. No acute or sustained 
changes were found in renal cortical or medullary tissue oxygenation. It remains to be determined whether this is the case in 
nondiabetic or diabetic patients with congestive heart failure or kidney disease.
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Empagliflozin is a sodium/glucose cotransporter 2 inhibitor (SGLT2i) used for the treatment of type 2 diabetes mellitus (T2DM) with the unique property of decreasing blood glucose independently from insulin, by enhancing renal glucose excretion. The recent 2019 European Society of Cardiology guidelines developed 
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in collaboration with the European Association for the 
Study of Diabetes recommend SGLT2i as initial ther-
apy for patients with T2DM at high risk of cardiovascu-
lar disease to reduce cardiovascular and renal events 
and hospitalization for heart failure. The guidelines also 
recommend empagliflozin to reduce mortality in those 
with established cardiovascular disease.1
Although landmark studies with SGLT2 inhibi-
tors included T2DM individuals, there is growing evi-
dence that the cardiorenal protective effects of SGLT2 
inhibitors are due to mechanisms beyond glucose con-
trol. Randomized, controlled trials and observational 
studies with SGLT2 inhibitors showed renal protec-
tive effects independent from glucose control.2,3 Very 
recently, the Dapagliflozin and Prevention of Adverse 
Outcomes in Heart Failure study demonstrated a sig-
nificant decrease in worsening of heart failure or death 
in nondiabetic individuals with reduced ejection frac-
tion.4 Rapid forced diuresis with SGLT2 inhibition has 
salutary hemodynamic effects on the heart in people 
with high cardiovascular risk. The effect on the kidney 
is more complex. SGLT2 inhibitors decrease the con-
comitant active reabsorption of sodium and glucose 
in the proximal tubule. They also induce an acute and 
reversible decrease in estimated glomerular filtration 
rate and albuminuria followed by a long- term slowing 
of estimated glomerular filtration rate decline and albu-
minuria progression.3,5 Several potential mechanisms 
may explain the beneficial effects of SGLT2i on renal 
disease progression, such as a decrease in glomer-
ular hyperfiltration, a reduction in blood pressure, and 
an increase in urinary sodium excretion.6–8 Because 
active sodium reabsorption is the main determinant of 
renal oxygen consumption, many have hypothesized 
that SGLT2 inhibition may lead to a decrease in corti-
cal oxygen utilization and an increase in tissue oxygen-
ation, and thereby protect kidney function.9,10 Recent 
studies have shown a significant association between 
cortical renal tissue oxygenation and the progression 
of chronic kidney disease in humans.11 It is currently not 
known whether the nephroprotective effects of SGLT2 
inhibitors are related to improved renal oxygenation.
Mechanistic studies involving cardiorenal interac-
tions are important because of the growing interest of 
SGLT inhibition in nondiabetic individuals. The primary 
aim of this study was therefore to explore the acute 
and sustained effects of empagliflozin on renal tissue 
oxygenation as measured noninvasively with blood- 
oxygenation- level–dependent magnetic resonance 
imaging (BOLD- MRI) in nondiabetic normotensive 
subjects, and the secondary aims were to assess the 
effect of empagliflozin on blood pressure control and 
renal tubular function in nondiabetic subjects. Another 
reason to investigate nondiabetic subjects was to avoid 
the confounding factor of blood glucose fluctuations in 
diabetes mellitus on the BOLD- MRI signal, as recently 
described by our group.12,13
METHODS
The details of the study protocol have been pub-
lished elsewhere.14 This monocentric research pro-
ject was approved by the local institutional review 
committee (ethics committee of the Canton de Vaud, 
Switzerland) and conducted according to the princi-
ples of the Declaration of Helsinki. Written informed 
CLINICAL PERSPECTIVE
What Is New?
•  This is the first study to examine the acute and 
chronic effects of sodium/glucose cotransporter 
2 inhibition on renal oxygenation, as determined 
by renal blood-oxygenation-level–dependent 
magnetic resonance imaging.
•  Acute and sustained sodium/glucose cotrans-
porter 2 inhibition with empagliflozin does not 
alter renal oxygenation in nondiabetic normo-
tensive subjects in spite of significant tubular 
and blood pressure effects.
What Are the Clinical Implications?
•  The observed metabolic changes are similar to 
the effects known in type 2 diabetic subjects, 
namely increased natriuresis, glucosuria, de-
creased blood pressure and uric acid levels, 
and increased hemoglobin; these effects will 
likely be beneficial to a larger population of non-
diabetic subjects.
•  Renal tissue oxygenation, renal function, and 
electrolytes did not change, compatible with a 
favorable renal profile of this drug in nondiabetic 
subjects
•  Endogenous lithium clearance studies show 
that natriuresis was the result of reduced reab-
sorption of sodium in proximal tubuli, illustrating 
why sodium/glucose cotransporter 2 inhibitors 
have added value on top of more distally active 
diuretics, such as loop diuretics.
Nonstandard Abbreviations and Acronyms
AP    acute phase
BOLD-MRI    blood oxygenation-level–dependent 
magnetic resonance imaging
CP    chronic phase
SGLT2    sodium/glucose cotransporter 2
SGLT2i    sodium/glucose cotransporter 2 inhibitor
T2DM    type 2 diabetes mellitus
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consent was obtained from all participants. The data 
that support the findings of this study are available 
from the corresponding author upon reasonable 
request.
Trial Design
This is a double- blind, randomized, placebo- controlled 
study addressing the acute and chronic renal effects of 
10 mg empagliflozin given orally in healthy, nonmedi-
cated volunteers.
Study Participants
In brief, a total of 45 healthy volunteers, 18 to 50 years 
of age, were recruited. Inclusion criteria were absence 
of diabetes mellitus based on glycated hemoglobin 
(<6.5%) and oral glucose tolerance (<7 mmol/L fasting, 
<11.1 mmol/L after 75 g of glucose) testing, a Chronic 
Kidney Disease Epidemiology Collaboration–based 
estimated glomerular filtration rate >60  mL/min per 
1.73 m², a urine albumin/creatinine ratio <3.3 mg/mmol, 
a normal urine dipstick, normal hematology and chem-
istry results, and a normal renal ultrasound. Among the 
exclusion criteria were a history of substance abuse 
and claustrophobia or another contraindication for MRI 
(pregnancy, implanted metallic devices). Each group 
was randomized to placebo (n=15) or empagliflozin 
(n=30). The randomization procedure was done by 
the hospital’s pharmacy on the first day of the acute 
phase. A 2:1 randomization was chosen to compen-
sate for the possible higher dropout rate in the empa-
gliflozin group due to side effects. Empagliflozin 10 mg 
or placebo tablets were identical in size and stored in 
similar boxes containing 30 tablets. Investigators (re-
search nurses, doctors, and technicians) were blinded 
to treatment.
Intervention
At baseline, each subject underwent 24- hour ambu-
latory blood pressure monitoring (Diasys, Physicor, 
Geneva, Switzerland) and a 24- hour urine collection 
without any treatment. Renal ultrasound was per-
formed using an Aplio XG device (Toshiba Medical 
Systems, Volketswil, Switzerland). The renal resistive 
indexes were measured on three segmental arteries 
(superior, middle, and inferior) in each kidney and av-
eraged. Volunteers were instructed not to smoke or 
drink alcohol or have any caffeine- containing bever-
age during the study days. On the following morn-
ing, after a light breakfast at home at 7:00 AM, the 
volunteer arrived at the study center at 9:00 AM and 
stayed the whole day (acute phase [AP]). Serial blood 
and urine collections were performed at arrival and 
after a standardized hydration protocol at T0(AP), as 
well as 90 (T90(AP)) and 180 minutes (T180(AP)) after 
receiving the first oral administration of placebo or 
empagliflozin. Renal BOLD- MRI measurements were 
performed at T0(AP) and T180(AP) minutes. At com-
pletion of the study day, volunteers left the center 
and continued taking the tablet once a day in the 
morning for 4 weeks. During this period, they were 
examined once per week and received a telephone 
call on another day each week for safety reasons. On 
the day before taking the last tablet, both 24- hour 
ambulatory blood pressure monitoring and 24- hour 
urine collection were repeated. On the last day, simi-
lar assessments were performed throughout the day 
at the study center (chronic phase [CP]) before and 
after the last empagliflozin or placebo tablet, as dur-
ing the AP.
BOLD- MRI Analysis
BOLD- MRI uses the paramagnetic properties of de-
oxyhemoglobin. Increases in its outcome value R2* 
(apparent relaxation rate, expressed per second) cor-
responded to higher local deoxyhemoglobin levels and 
thus lower oxygenation.15 Twelve T2*- weighted MR im-
ages were acquired at one coronal slice within a single 
breath- hold on a 3- T whole- body magnetic resonance 
system (Magnetom Prisma, Siemens Medical Systems, 
Erlangen, Germany), using a previously described 
modified multiecho data image combination sequence 
for BOLD- MRI analysis. This procedure was repeated 
10 times. Images were imported for further analysis in 
MATLAB version 7.11 (The MathWorks, Natick, MA).16 
To minimize bias, we only included BOLD- MRIs that 
had a minimum of 8 of 10 series with excellent image 
quality. After image selection, the 12- layer concentric 
objects method was used to analyze the images, as 
reported elsewhere.16
The mean R2* value of the outer 3 layers of the 
two kidneys was used as a proxy of renal cortical 
oxygenation, and the mean R2* value of the inner 
(eighth through tenth) layers was used to report med-
ullary oxygenation. The slope of the linear part of the 
R2* curve was expressed as the change in hertz per 
percentage change of depth, and its regression co-
efficient, β, was calculated using linear least- square 
regression.
Biochemical Measurements
Plasma and urine samples were analyzed for glu-
cose, urea nitrogen, creatinine, urate, and sodium, 
using routine clinical chemistry methods on a Cobas 
8000 device (Roche Diagnostics System, Basel, 
Switzerland). Proximal renal sodium handling was 
assessed by determination of fractional excretion 
of endogeneous lithium (FELi), a proxy of proximal 
sodium reabsorption, as described previously.17 
The fractional excretion of lithium (FELi) and sodium 
(FENa) were assessed using the standard formula 
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(FEx=(Ux×Pcreatinine) / (Px×Ucreatinine)), with U and P rep-
resenting urine and plasma concentrations of sodium 
or lithium.
Hormones
Plasma renin activity was measured using a com-
mercial radioimmunoassay kit for the quantitative 
determination of angiotensin I in human plasma, 
whereas aldosterone quantification in blood was 
performed with the Aldo- Riact RIA kit (both kits from 
CISBio International, Yvette, France). Total plasma 
erythropoietin concentrations were determined 
using a solid- phase sandwich ELISA kit (Human 
Erythropoietin Quantikine IVD ELISA Kit; R&D 
Systems, Minneapolis, MN).
Outcomes
The primary outcome measures were the acute and 
chronic effects of empagliflozin on renal tissue oxy-
genation as measured by BOLD- MRI. The secondary 
outcomes were the effects of empagliflozin on body 
weight, office blood pressure and 24- hour blood pres-
sure measurements, renal tubular function, erythro-
poietin, hematocrit, and ultrasound- assessed renal 
resistance indexes and length.
Statistical Analysis
Sample size calculation was based on the assump-
tion that empagliflozin would improve oxygenation 
by 10% (corresponding to an approximate decrease 
in cortical R2* of 2 per second) with a sigma (SD) of 
5% (1 per second). As empagliflozin influences sodium 
reabsorption in proximal tubuli, we based this estima-
tion and SD on our previous BOLD- MRI studies that 
examined the influence of tubular sodium handling on 
tissue oxygenation. Dietary interventions that altered 
tubular sodium transport (a change in dietary sodium 
intake) induced R2* changes of ≈10%, albeit in the me-
dulla.18 Another study showed that furosemide induced 
medullary changes of R2*≈15%, and cortical changes 
of ≈5%.19 Previous intervention studies have not often 
focused on drugs with mainly cortical actions, with the 
exception of a study by Schachinger et al,20 where in-
travenous perfusion of angiotensin II altered cortical 
T2* (and thus R2*) by ≈10%. Finally, in animal studies 
with direct measurement of oxygenation by microelec-
trodes, cortical PO2 increased by ≈20% after phlorizin 
in streptozotocin- induced diabetic rats, whereas no 
changes were seen in control Sprague- Dawley rats. 
On the basis of these data, we therefore decided 
to choose 10% as expected R2* change. This also 
seemed to be a clinically significant value. As such, 
the sample size required to demonstrate a significant 
effect with a power of 90% and an α type I error of 5% 
was 15 subjects per group14; 10 subjects per group 
were needed to have a power of 80%.
Statistical analysis was performed using STATA 
version 14.0 (StataCorp, College Station, TX). 
Quantitative variables are expressed as mean±SD, 
and qualitative variables are expressed as number of 
volunteers and percentage. Test of normality was per-
formed followed by ANOVA or Student t test when ap-
propriate. For repeated measurements, we performed 
a repeated- measures ANOVA that analyzes between- 
subjects (treatment) and within- subjects (time) effects. 
The treatment×time interaction was used to examine 
the treatment influences over time. In case of a signif-
icant treatment×time interaction by ANOVA, a test for 
simple effects was performed for analysis of the effect 
Table 1. Clinical Characteristics of Enrolled Volunteers by Randomization 
Placebo (n=15) Empagliflozin (n=30)
Age, y 34.1±10.6 32.7±7.5 NS
Weight 86.5±21.8 84.4±18.9 NS
BMI, kg/m2 28.1±4.7 28.2±5.3 NS
Sex, males/females 8/7 19/11 NS
Ethnicity (%) African, Asian, white, other 20/0/73.3/6.7 6.7/6.7/66.7/20 NS
Office systolic blood pressure, mm Hg 118.2±9.6 120.9±12.2 NS
Office diastolic blood pressure, mm Hg 71.5±7.5 71.9±7.9 NS
Pulse rate, bpm 68.0±11.4 69.7±9.8 NS
eGFR, mL/min per 1.73 m2 113.1±12.4 112.9±11.5 NS
Urinary albumin/creatinine ratio <3 mg/
mmol, %
100 100 NS
Fasting plasma glucose, mmol/L 5.0±0.7 5.0±0.4 NS
Plasma glucose 2 h after 75 g glucose, 
mmol/L
4.4±1.2 5.5±1.7 0.03
HbA1C, % 5.4±0.3 5.4±0.3 NS
Data expressed as mean±SD. Placebo and empagliflozin groups compared using unpaired two- sample t tests. BMI indicates body mass index; bpm, beats 
per minute; eGFR, estimated glomerular filtration rate; HbA1C, glycated hemoglobin; and NS, not statistically significant.
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of treatment at each timepoint in comparison to the 
T0 of the treatment group. In case of non- normality, 
a Wilcoxon matched- pairs signed- rank test was per-
formed. P<0.05 was considered significant.
RESULTS
From March 2017 to October 2018, 79 healthy volun-
teers were screened, among whom 34 were excluded 
because of exclusion criteria and 45 were randomized 
to placebo (n=15) or empagliflozin 10  mg (n=30). All 
subjects completed the AP, whereas 13 subjects in 
the placebo group (86.7%) and 27 in the empagliflozin 
group (90%) completed the CP (Figure S1).
Baseline characteristics of the study groups are 
presented in Table 1. Average age, weight, body mass 
index, sex distribution, office blood pressure, and heart 
rate did not differ between groups. Blood glucose was 
similar at baseline in both groups but slightly higher in 
the empagliflozin group 2 hours after 75 g of glucose.
RENAL BOLD- MRI
Table 2 and Figure 1 present the effects of empagliflozin 
or placebo on renal tissue oxygenation, as measured 
by the BOLD- MRI technique. Thirteen volunteers com-
pleted the first- and last- dose assessment in the placebo 
group and 27 in the empagliflozin group. Based on the 
strict criteria of image selection, 12 and 21 volunteers, 
respectively, passed the image selection criteria at all 4 
sessions, as compared with 15 and 26 volunteers before 
and after the first dose. As such, a total of 148 BOLD- MRI 
exams were included in the analysis (Figure S2). Table 2 
summarizes the mean cortical and medullary R* values 
and the slope of the right and left kidney R2* curves. 
Figure 1 illustrates the curves before and 180 minutes 
after the first (Figure A, B) and last tablet (Figure C and 
D) and at baseline (before drug intake) and after 1 month 
of treatment (Figure E and F). Empagliflozin and placebo 
effects on cortical and medullary R2* values did not 
differ 180 minutes after the first tablet or 180 minutes 
after the last tablet. After 1 month of treatment there was 
also no change in cortical R2* with placebo or empa-
gliflozin (+0.4±0.6 and −0.4±0.2, respectively). After 1 
month of treatment there was no change in medullary 
R2* with placebo and empagliflozin (+0.29±0.50 and 
−0.03±0.33, respectively). The slopes of right and left 
kidney R2* curves did not differ by treatment.
BIOCHEMICAL AND RENAL EFFECTS 
DURING AP AND CP
The biochemical and hormonal variations from base-
line to 90 and 180 minutes after the first tablet (AP) and 
after the last tablet (CP after 1- month treatment) are 
detailed in Table 3.
Blood
Plasma glucose remained the same with placebo and 
empagliflozin 180 minutes after the first and last tablet. 
Overall, treatment had no significant acute effect on 
hemoglobin, hematocrit, plasma creatinine, sodium, 
potassium, and urate levels, although there was a clear 
trend toward an increase in hemoglobin and creatinine 
after the first dose of empagliflozin. The observed de-
crease in urea on first and last drug administration was 
most probably due to the hydration protocol as similar 
changes were observed with placebo.
Spot urine
The increase in urinary glucose/creatinine ratio was 
rapid and significant already 90 minutes after the first 
dose of empagliflozin, and rose higher at 180 minutes. 
After 1 month of treatment with empagliflozin, glu-
cose/creatinine ratio was already high at baseline and 
increased further at 180 minutes after the last empa-
gliflozin tablet. There was a nonsignificant decrease in 
FENa and FELi at 90 and 180 minutes with placebo sug-
gesting sodium retention per protocol due to the fasting 




Baseline 1- Month Treatment Baseline 1- Month Treatment
T0(AP) T180(AP) T0(CP) T180(CP) T0(AP) T180(AP) T0(CP) T180(CP)
Outer R2* (s−1)* 20.6±1.3 21.5±1.9 21.0±2.4 20.5±1.3 20.1±1.9 20.5±2.1 19.8±1.8 20.3±2.2 0.09
Inner R2* (s–1)† 23.9±1.7 24.7±2.0 24.2±1.9 24±1.6 23.9±1.7 24.6±2.1 23.9±1.5 24.4±1.9 0.7
Slope R (%)‡ 12±6 11±5 12±5 12±4 13±4 13±3 12±3 13±5 0.5
Slope L (%)‡ 12±5 13±5 12±5 12±4 12±5 12±5 13±5 11±4 0.7
For comparison, data from subjects having completed all four BOLD- MRIs are presented (n=12 placebo; n=21 empagliflozin). Data show results of repeated- 
measures analysis with P value for time×treatment effect. BOLD- MRI indicates blood- oxygen- level–dependent magnetic resonance imaging; T0(AP), time 0 min 
(acute phase); T180(AP), time 180 min (acute phase); T0(CP), time 0 (chronic phase); T180(CP), time 180 min (chronic phase).
*Outer R2* = mean R2* of the three most superficial, cortical layers of renal parenchyma.
†Inner R2* = mean R2* of the eighth to tenth layer (corresponding to medulla) of renal parenchyma.
‡Slope = hertz per percent depth.
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state. In contrast, there was a sharp and significant in-
crease in FENa and a moderate increase in FELi after the 
first empagliflozin tablet, suggesting a natriuretic effect 
of empagliflozin due to reduced reabsorption of sodium 
in the proximal tubule. Increases in FENa and FELi were 
more modest after 1 month of therapy. For comparison, 
the percent changes in FELi from T0(AP) and T180(AP) 
were −21.8% and +12.8% with placebo and empagliflo-
zin (+34.6% empagliflozin- induced difference), respec-
tively, showing proximal sodium retention per protocol 
with placebo but increase in proximal sodium excretion 
with empagliflozin that persisted after 1 month but to a 
milder degree. Likewise, the percent changes in FENa 
from T0(AP) and T180(AP) were −11.5% and +35.6% 
with placebo and empagliflozin (+47.1% empagliflozin- 
induced difference), respectively, and from T0(CP) and 
T180(CP) of −13.0% and +8.0% (+21% empagliflozin- 
induced difference).
CLINICAL, BIOCHEMICAL, AND 
RENAL EFFECTS BEFORE AND 
AFTER 1- MONTH TREATMENT
Changes in Body Weight and Blood Pressure
Weight did not change with placebo (Table 4). There 
was a clear trend toward a decrease in weight in the 
empagliflozin group, which was significant after 1 
Figure 1. Placebo and empagliflozin R2* profile graphs summarizing the mean±SD R2* of the 12 layers. 
The percentage scale refers to the relative depth of each layer. The deepest layers are in the medulla and 
have a higher R2*, and thus lower oxygenation. A and B, Curves before and after the first tablet (acute 
phase, T0(AP) and T180(AP)). C and D, Curves before and after the last tablet (chronic phase, T0(CP) and 
T180(CP)). E and F, Curves at baseline and after 1 month of treatment (T0(AP) and T0(CP)).
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and 2 weeks. At 4 weeks, however, the differences 
in weight were no longer significant (Table 4). Office 
systolic and diastolic blood pressures and heart rate 
were similar at baseline and after 1 month of placebo. 
Office systolic blood pressure decreased by an aver-
age of 4.0  mm  Hg with empagliflozin (P=0.05), but 
office diastolic blood pressure and heart rate did 
not differ. Twenty- four- hour ambulatory blood pres-
sure measurements showed significant decreases 
in systolic (mean±SD: placebo, +2.8±6.3  mm  Hg; 
empagliflozin, −5.1±6.7  mm  Hg; P=0.0005) and di-
astolic (placebo, +1.5±4.4  mm  Hg; empagliflozin, 
−2.0±5.5 mm Hg; P=0.03) blood pressure with em-
pagliflozin (Figure 2).
Biochemical and hormonal changes after 
1- month treatment
Creatinine clearance, 24- hour urinary sodium excre-
tion, sodium, potassium, urate, and hormonal pa-
rameters (plasma renin activity, aldosterone) were 
not different between groups at baseline (Table 4). 
Fasting plasma glucose, insulin, and Homeostatic 
Model of Insulin Resistance insulin resistance 
index did not change in both groups. Urinary 
glucose/creatinine ratio increased with empa-
gliflozin in all volunteers. Total urinary glucose ex-
cretion ranged between 0.4±0.2 to 0.5±0.3  mmol 
at baseline or with placebo, whereas it increased to 
285.4±85.8 mmol (51.4±15.4 g) after 1- month treat-
ment with empagliflozin.
Fasting hemoglobin and hematocrit were similar 
at baseline in both groups. After 1- month treatment, 
hemoglobin and hematocrit levels increased with 
empagliflozin. Erythropoietin levels did not change 
from baseline to 1- month therapy with empagliflozin 
(60.3±30.8  pg/mL at baseline and 60.3±25.1  pg/mL 
after 1- month treatment).
Plasma sodium, potassium, and creatinine levels 
remained the same in both groups. Creatinine 
clearance did not change. Plasma uric acid lev-
els decreased significantly with empagliflozin 
(−86±36 μmol/L, P<0.0001).
Total 24- hour urinary sodium excretions were 
182±63  mmol and 203±93  mmol at baseline, re-
spectively, in the placebo and empagliflozin groups 
and did not change significantly after 1- month treat-
ment. Twenty- four- hour FENa did not vary after 1 
month of treatment, whereas FELi increased signifi-
cantly with empagliflozin (Table  4). Plasma aldoste-
rone levels increased significantly with empagliflozin 
(+36.9±61.3  pmol/L, P=0.002), as did plasma renin 
activity (+0.18±0.41 ng/mL per hour, P=0.02).
Significant 24- hour blood pressure changes and 
biochemical changes in renal BOLD- MRI measure-
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Renal Ultrasound
Renal resistance indexes remained the same with pla-
cebo and empagliflozin (delta differences [mean±SD]: 
right kidney: placebo, −0.001±0.132; empagliflozin, 
−0.014±0.147; left kidney: placebo, −0.005±0.053; 
empagliflozin, −0.017±0.080). Renal lengths also did 
not change with placebo and empagliflozin (delta dif-
ferences: right kidney: placebo, −0.47±4.46; empa-
gliflozin, 0.97±5.47; left kidney: placebo, 1.75±6.31; 
empagliflozin, −1.04±5.69).
DISCUSSION
This study has shown that, in healthy normotensive 
and nondiabetic subjects, empagliflozin decreases 
24- hour systolic blood pressure by 5  mm  Hg with 
significant renal tubular effects (Tables  3 and 4, 
Figure 2), but with no alteration of renal tissue oxy-
genation in the cortex or in the medulla (Table  2, 
Figure  1). This observation was made despite the 
fact that empagliflozin increased urinary glucose and 
proximal sodium excretion both acutely and chroni-
cally, as reflected by changes in fractional excretion 
of endogenous lithium (Tables 3 and 4). Chronically, 
however, the increase in aldosterone contributed 
to counteract the natriuretic effect of empagliflozin 
(Table  4). Empagliflozin also increased hemoglobin, 
decreased serum uric acid, and stimulated the renin- 
angiotensin system (Table 4).
The primary hypothesis of this study, namely that 
empagliflozin increases cortical oxygenation by 10%, 
was not confirmed in these nondiabetic, normotensive 
subjects (Table 2, Figure 1). The absence of changes 
in cortical oxygenation may seem surprising in the 
context of a marked reduction in oxygen- consuming 
glucose and sodium reabsorption in the cortical proxi-
mal tubules. Although renal sodium handling is a major 
determinant of oxygen consumption by kidneys, a first 
explanation may be that changes in oxygenation were 
too modest to affect the BOLD- MRI signal. In this con-
text, Prasad et al did not observe significant changes in 
cortical R2* values after a single dose of acetazolamide 
(a diuretic acting on the proximal tubules).15 However, 
their study was performed in only six subjects at 1.5 
T. Since then, studies performed at higher magnetic 
field strength have shown that changes in cortical R2* 
of 5% to 10% can be observed with other drugs such 
as angiotensin- converting enzyme inhibitors and nitric 
oxide synthase inhibitors.21,22 Hence, BOLD- MRI per-
formed at 3 T in our study should be sensitive enough 
to capture drug- induced changes in cortical oxygen-
ation if they are large enough.
As oxygen- consuming sodium transport is the 
main determinant of renal tissue oxygenation, an-
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with empagliflozin were not large or acute enough 
to alter oxygenation. Studies showed that extreme 
changes in sodium intake (>10- fold) altered medul-
lary but not cortical oxygenation in healthy volun-
teers.18 Furthermore, in humans, the only diuretic 
demonstrating short- term effects on renal tissue ox-
ygenation thus far is intravenously administered furo-
semide.12 This loop diuretic induces acute natriuresis 
around 8- fold higher than the 0.1- mol/min increase 
with empagliflozin in our study.
Our results are in line with a previous study in 
Sprague- Dawley rats that also showed no change in 
cortical PO2 as measured with Clark microelectrodes 
after a single dose of phlorizin. However, medullary 
PO2 decreased in these healthy rats, which was ex-
plained by the authors as a shift in active Na+ transport 
from proximal to more distal nephron segments.23 In 
contrast, in rats with streptozotocin- induced diabe-
tes mellitus, phlorizin restored the decreased corti-
cal oxygen tension to normal levels while decreasing 
medullary oxygen tension. In another study using a 
computational rat kidney model, it was predicted that 
SGLT2 inhibition would shift oxygen- consuming ac-
tive transport to the medulla and enhance hypoxia.9 
In this sense, our data are reassuring as the shift to 
more distal nephrons did not lead to a decrease in 
medullary oxygenation measured with BOLD- MRI 
in humans, as previously hypothesized by Heyman 
et al.24,25
One should keep in mind that our study enrolled 
healthy subjects with a normal renal function and no 
proteinuria. We primarily included healthy subjects 
to study the effects of empagliflozin in those without 
diabetes mellitus, but also to avoid the confounding 
factor of blood glucose fluctuations on the BOLD- 
MRI signal, as recently described by our group.12,13 
It remains to be demonstrated whether empagli-
flozin has a similar impact on patients with diabetes 
mellitus characterized by glomerular hyperfiltration 
and excessive sodium reabsorption in the proximal 
tubules.
In this study we have demonstrated that empagli-
flozin decreases the reabsorption of sodium in the 
proximal tubule using an endogenous lithium clear-
ance technique (Table 3). Fractional excretion of lithium 
is a reliable marker of proximal sodium reabsorption as 
lithium is reabsorbed in parallel to water and sodium in 
the early segments of the proximal tubules. The princi-
ple of using endogenous lithium as a marker of proxi-
mal sodium reabsorption is that lithium is normally not 
reabsorbed in postproximal segments. Lithium trans-
port in the thick ascending limb is not impossible and, 
in the more distal segment, lithium may be reabsorbed 
in cases of dehydration and a stimulated vasopressin 
system.26 However, in our study, subjects were well hy-
drated per protocol and avoided distal reabsorption27 
despite a possible stimulation of vasopressin, as sug-
gested by Eickhoff et al.28 Moreover, the early segments 
of the proximal tubule in which lithium is reabsorbed are 
also those where SGLT2 modulates glucose reabsorp-
tion. Our observation confirms a recent observation in 
T2DM subjects indicating that dapagliflozin increased 
fractional excretion of lithium by an average of 19.6%.28 
Likewise, there was a compensatory activation of the 
Figure 2. Summary of significant variations from baseline to 1- month treatment in placebo and empagliflozin groups. Data are 
expressed as mean±SEM. Delta variations in placebo and empagliflozin groups were compared by unpaired two- sample t tests. 
BOLD- MRI indicates blood oxygenation- level–dependent magnetic resonance imaging; DBP, diastolic blood pressure; FELi, fractional 








































J Am Heart Assoc. 2020;9:e016173. DOI: 10.1161/JAHA.119.016173 12
Zanchi et al Empagliflozin and Renal Oxygenation by BOLD- MRI
renin- angiotensin system. Interestingly, in our study, 
in spite of these compensatory mechanisms, 24- hour 
systolic blood pressure decreased by an average of 
5.1 mm Hg after 1 month of empagliflozin in normoten-
sive subjects. This response is even more pronounced 
than that seen after 3- month treatment in patients with 
T2DM and hypertension.29 The mechanisms of blood 
pressure reduction were independent of weight control 
but may be related to mild volume contraction, as sug-
gested by the increase in hemoglobin and hematocrit.
When comparing these data with those seen in 
T2DM patients, although the effects on 24- hour glucos-
uria are milder,30 the lowering effects on systolic blood 
pressure29 and plasma uric acid levels seem more pro-
nounced.31 However, the decrease in proximal sodium 
reabsorption and activation of the renin- angiotensin sys-
tem are comparable.28 Finally, we could not demonstrate 
any increase in erythropoietin levels at 1 month, in con-
trast to T2DM patients with coronary artery disease.32 
These similarities and differences should be considered 
when comparing our neutral results of SGLT2 inhibition 
on renal BOLD- MRI measurements with future studies.
Our study has both limitations and strengths. As we 
used very strict selection criteria for image quality and 
anatomic coherence to minimize bias, a certain number 
of subjects were excluded from analysis. In addition, 
the chosen threshold of a hypothetical empagliflozin- 
induced change of 10% in R2* was empirical. However, 
the observed changes in R2* were minimal between 
the visits, underlining the high reproducibility of BOLD- 
MRI. Another limitation is that our study cohort included 
normotensive, young healthy volunteers. It is not known 
whether these the results can be generalized to patients 
with T2DM at risk of diabetic kidney disease.
In summary, this is the first study to examine simul-
taneously the effects of empagliflozin on renal oxygen-
ation, tubular sodium transport, and blood pressure 
in humans. We have demonstrated that empagliflozin 
has beneficial metabolic and blood pressure effects 
but does not affect renal tissue oxygenation acutely or 
chronically in nondiabetic subjects with normal renal 
function. It remains to be explored whether these re-
sults can be generalized to diabetic or nondiabetic pa-
tients with congestive heart failure or kidney disease.
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Acute phase (AP), Chronic phase (CP) with 24h urine collections, 24h ambulatory blood pressure measurements, blood and urine sampling and 
renal BOLD-MRI sessions. T0 (baseline before pill), T90, T120 (90 and 120 minutes after oral pill), SAE: serious adverse effect 





Three volunteers enrolled in the empagliflozin group did not terminate the study (2 for hospitalizations 
not related to empagliflozin and one due to study pause unrelated to volunteer), and two in the placebo 
group (one for hypotension and dehydration and the other for study pause unrelated to volunteer). 
Following the 2 hospitalizations, the study was paused for 2 weeks waiting for the approval from the 
national health regulating authorities Swissmedic and the ethical committee to confirm that these 
events were not related to the study drug and the permission to complete the study.  
 
